Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Reexamination Certificate
2007-05-30
2010-10-05
Haddad, Maher M (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
C424S145100, C530S387300, C530S388230
Reexamination Certificate
active
07807161
ABSTRACT:
The present invention provides a humanized anti-human osteopontin antibody having better activities (antigen binding activity, leukocyte migration inhibitory activity and the like) and/or stability (resistance to heat, low-pH conditions, denaturants and the like) than those of conventional anti-human osteopontin antibodies.
REFERENCES:
patent: 5854027 (1998-12-01), Steipe et al.
patent: 5859205 (1999-01-01), Adair et al.
patent: 7241873 (2007-07-01), Uede et al.
patent: 7456260 (2008-11-01), Rybak et al.
patent: 2004/0234524 (2004-11-01), Uede et al.
patent: 2008/0138860 (2008-06-01), Torikai et al.
patent: 0 239 400 (1987-09-01), None
patent: 1 637 159 (2006-03-01), None
patent: WO 90/07861 (1990-07-01), None
patent: WO 9802462 (1998-01-01), None
patent: WO 03/008451 (2003-01-01), None
patent: WO 03/008451 (2003-01-01), None
patent: WO 03/027151 (2003-04-01), None
patent: WO 2006/043954 (2006-04-01), None
Nieba et al. Disrupting the hydrophobic patches at the antibody variable/ constant domain interface: improved in vivo folding and physical characterization of an engineered scFv fragment. Protein Engineering vol. 10 No. 4 pp. 435-444, 1997.
Philip M. Green et al.; “Structural elements of the osteopontin SVVYGLR motif important for the interaction with a4 integrins”; FEBS Letters 503, 2001, pp. 75-79.
Diosdado S. Bautista et al; “Inhibition of Arg-Gly-Asp (RGD)-mediated Cell Adhesion of Osteopontin by a Monoclonal Antibody against Osteopontin”; The Journal of Biological Chemistry, vol. 269, No. 37, Issue of Sep. 16, 1994, pp. 23280-23285.
Simon T. Barry et al.; “Analysis of the a4b1 Integrin-Osteopontin Interation”; Experimental Cell Research 258, 2000, pp. 342-351.
Yasuyuki Yokosaki et al; “The Integrin a9B1 Binds to a Novel Recognition Sequence (svvyglr) in the Thrombin-cleaved Amino-terminal Fragment of Osteopontin” The Jourmal of Biological Chemistry, vol. 274, No. 51 Issue of Dec. 17, 1999, pp. 36328-36334.
U.S. Appl. No. 11/836,078, filed Aug. 8, 2007, Uede, et al.
Stefan Ewert, et al., “Stability improvement of antibodies for extracellular and intracellular applications: CDR grafting to stable frameworks and structure-based framework engineering”, Methods: A Companion to Methods in Enzymology, vol. 34, No. 2, XP004526805, Oct. 1, 2004, pp. 184-199.
Arne Wörn, et al., “Stability Engineering of Antibody Single-chain Fv Fragments”, Journal of Molecular Biology, vol. 305, No. 5, XP004465987, Feb. 2, 2001, pp. 989-1010.
Yoshiki Saitoh, “Expression of Osteopontin in Human Glioma Its Correlation with the Malignancy”; Laboratory Investigation, vol. 72, No. 1, pp. 55, 1995.
Poul Freese et al.; “Chronic allograft nephropathy-biopsy findings and outcome”; Nephrol Dial Transplant (2001) 16: pp. 2401-2406.
J.R. Waller et al.; “Molecular mechanisms of renal allograft firbosis”; British Journal of Surgery 2001, 88, pp. 1429-1441.
Transplantation, The Official Journal of the Transplantation Society, vol. 72(6), Sep. 27, 2001, pp. 1138-1144.
Anthony O'Regan et al.; “Osteopontin: a key cytokine in cell-mediated and granulomatous inflammation”; Blackwell Scienct Ltd. Int. J. Exp. Path. (2000), 81, pp. 373-390.
Shigeyuki Kon et al.; “Mapping of Functional Epitopes of Osteopontin by Monoclonal Antibodies Raised Against Defined Internal Sequences”; Journal of Cellular Biochemistry, 84: 420-432, 2000.
D. S. Bautista et al; “A Monoclonal Antibody against Osteopontin Inhibits RGD-Mediated Cell Adhesion to Osteopontin”; Annals New York Academy of Sciences, vol. 760, 1995, pp. 309-311.
Nobuchika Yamamoto et al; “Essential role of the cryptic epitope SLAYGLR within osteopontin in a murine model of rheumatoid arthritis”; The Journal of Clinical Investigation, Jul. 2003, vol. 112, No. 2, pp. 181-188.
Georg F. Weber; “The metastasis gene osteopontin: a candidate target for cancer therapy”; Biochimica et Biophysica Acta 1552, (2001), pp. 61-85.
Hema Rangaswami et al; “Osteopontin: role in cell signaling and cancer progression”; Trends in Cell Biology, vol. 16, No. 2, Feb. 2006; pp. 79-87.
Shiva S. Forootan et al; “Prognostic significance of osteopontin expression in human prostate cancer”; Int. J. Cancer: 118, (2006), pp. 2255-2261.
Zhi Hu et al; “Overexpression of Osteopontin is Associated with More Aggressive Phenotypes in Human Non-Small Cell Lung Cancer”; Clin Cancer Res (2005); vol. 11, No. 13, Jul. 1, 2005, pp. 4646-4652.
Sung Sup Park et al.; “Stability of murine, chimeric and humanized antibodies against pre-S2 surface antigen of hepatitis B virus”; Biologicals 31 (2005), pp. 295-302.
Robert F. Kelley et al; “Antigen Binding Thermodynamics and Antiproliferative Effects of Chimeric and Humanized anti-p185HER2 Antibody Fab Fragments”; Biochemistry 1002, 31; pp. 5434-5441, 1992.
William F. Dall'Acqua, et al. “Antibody humanization by framework shuffling” Methods, 36 (2005) pp. 43-60.
ZhuoZhi Wang, et al., “Humanization of a mouse monoclonal antibody neutralizing TNF-α by guided selection”, Journal of Immunological Methods, 241 (2000) pp. 171-184.
Manuel Baca, et al, “Antibody Humanization Using Monovalent Phage Display”, The Journal of Biological Chemistry, vol. 272, No. 16, Issue of Apr. 18, pp. 10678-10684, 1997.
Higuchi Hirofumi
Nakashima Toshihiro
Sakai Fumihiko
Torikai Masaharu
Yamamoto Nobuchika
Astellas Pharma Inc.
Haddad Maher M
Juridical Foundation The Chemo-Sero-Therapeutic Research Institu
Oblon, Spivak McClelland, Maier & Neustadt, L.L.P.
LandOfFree
Humanized anti-human osteopontin antibody does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Humanized anti-human osteopontin antibody, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Humanized anti-human osteopontin antibody will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4167764